Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
MNTA's Cash to Debt is ranked higher than
94% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MNTA: No Debt )
MNTA' s 10-Year Cash to Debt Range
Min: 13.61   Max: No Debt
Current: No Debt

Equity to Asset 0.81
MNTA's Equity to Asset is ranked higher than
87% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. MNTA: 0.81 )
MNTA' s 10-Year Equity to Asset Range
Min: -0.86   Max: 0.96
Current: 0.81

-0.86
0.96
Interest Coverage No Debt
MNTA's Interest Coverage is ranked higher than
94% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. MNTA: No Debt )
MNTA' s 10-Year Interest Coverage Range
Min: 110.84   Max: 9999.99
Current: No Debt

110.84
9999.99
F-Score: 3
Z-Score: 7.74
M-Score: -3.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -190.23
MNTA's Operating margin (%) is ranked higher than
50% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. MNTA: -190.23 )
MNTA' s 10-Year Operating margin (%) Range
Min: -548.56   Max: 63.48
Current: -190.23

-548.56
63.48
Net-margin (%) -188.71
MNTA's Net-margin (%) is ranked higher than
50% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. MNTA: -188.71 )
MNTA' s 10-Year Net-margin (%) Range
Min: -546.42   Max: 63.71
Current: -188.71

-546.42
63.71
ROE (%) -42.88
MNTA's ROE (%) is ranked higher than
53% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. MNTA: -42.88 )
MNTA' s 10-Year ROE (%) Range
Min: -66.11   Max: 59.21
Current: -42.88

-66.11
59.21
ROA (%) -35.91
MNTA's ROA (%) is ranked higher than
53% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. MNTA: -35.91 )
MNTA' s 10-Year ROA (%) Range
Min: -389.52   Max: 55.62
Current: -35.91

-389.52
55.62
ROC (Joel Greenblatt) (%) -393.86
MNTA's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. MNTA: -393.86 )
MNTA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1125.81   Max: 348.38
Current: -393.86

-1125.81
348.38
Revenue Growth (3Y)(%) -43.40
MNTA's Revenue Growth (3Y)(%) is ranked lower than
51% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. MNTA: -43.40 )
MNTA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 138.6
Current: -43.4

0
138.6
» MNTA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MNTA Guru Trades in Q2 2014

Jim Simons 540,251 sh (+27.08%)
PRIMECAP Management 2,670,600 sh (+23.67%)
Steven Cohen 478,500 sh (unchged)
John Burbank Sold Out
Paul Tudor Jones Sold Out
Steven Cohen 2,395,088 sh (-18.58%)
» More
Q3 2014

MNTA Guru Trades in Q3 2014

Steven Cohen 554,400 sh (+15.86%)
PRIMECAP Management 2,670,600 sh (unchged)
Jim Simons 366,351 sh (-32.19%)
» More
Q4 2014

MNTA Guru Trades in Q4 2014

Chuck Royce 2,000 sh (New)
PRIMECAP Management 2,670,600 sh (unchged)
Jim Simons 230,351 sh (-37.12%)
Steven Cohen 302,800 sh (-45.38%)
» More
2015

MNTA Guru Trades in 2015

PRIMECAP Management 2,695,100 sh (+0.92%)
» More
» Details

Insider Trades

Latest Guru Trades with MNTA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 26.74
MNTA's Forward P/E is ranked higher than
81% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. MNTA: 26.74 )
N/A
P/B 3.87
MNTA's P/B is ranked higher than
67% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. MNTA: 3.87 )
MNTA' s 10-Year P/B Range
Min: 1.34   Max: 14.92
Current: 3.87

1.34
14.92
P/S 14.92
MNTA's P/S is ranked lower than
54% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. MNTA: 14.92 )
MNTA' s 10-Year P/S Range
Min: 1.84   Max: 60.6
Current: 14.92

1.84
60.6
EV-to-EBIT -6.41
MNTA's EV-to-EBIT is ranked higher than
64% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. MNTA: -6.41 )
MNTA' s 10-Year EV-to-EBIT Range
Min: -52.2   Max: 17.4
Current: -6.41

-52.2
17.4
Current Ratio 8.63
MNTA's Current Ratio is ranked higher than
93% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. MNTA: 8.63 )
MNTA' s 10-Year Current Ratio Range
Min: 1.71   Max: 24.92
Current: 8.63

1.71
24.92
Quick Ratio 8.63
MNTA's Quick Ratio is ranked higher than
94% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MNTA: 8.63 )
MNTA' s 10-Year Quick Ratio Range
Min: 1.71   Max: 24.92
Current: 8.63

1.71
24.92
Days Sales Outstanding 51.88
MNTA's Days Sales Outstanding is ranked higher than
85% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. MNTA: 51.88 )
MNTA' s 10-Year Days Sales Outstanding Range
Min: 36.32   Max: 506.58
Current: 51.88

36.32
506.58

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.64
MNTA's Price/Net Cash is ranked higher than
95% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNTA: 5.64 )
MNTA' s 10-Year Price/Net Cash Range
Min: 2.07   Max: 7.88
Current: 5.64

2.07
7.88
Price/Net Current Asset Value 5.14
MNTA's Price/Net Current Asset Value is ranked higher than
91% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNTA: 5.14 )
MNTA' s 10-Year Price/Net Current Asset Value Range
Min: 1.96   Max: 7.24
Current: 5.14

1.96
7.24
Price/Tangible Book 3.97
MNTA's Price/Tangible Book is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. MNTA: 3.97 )
MNTA' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 10.14
Current: 3.97

1.5
10.14
Price/DCF (Projected) 7.46
MNTA's Price/DCF (Projected) is ranked higher than
75% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. MNTA: 7.46 )
MNTA' s 10-Year Price/DCF (Projected) Range
Min: 1.86   Max: 5.96
Current: 7.46

1.86
5.96
Price/Median PS Value 0.78
MNTA's Price/Median PS Value is ranked higher than
94% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. MNTA: 0.78 )
MNTA' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 2.34
Current: 0.78

0.16
2.34
Earnings Yield (Greenblatt) -15.60
MNTA's Earnings Yield (Greenblatt) is ranked lower than
53% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MNTA: -15.60 )
MNTA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.8   Max: 78
Current: -15.6

5.8
78

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LZ1.Germany,
Momenta Pharmaceuticals Inc was incorporated in the state of Delaware in May 2001 under the name of Mimeon, Inc., later changed the name Momenta Pharmaceuticals, Inc. in September 2002. The Company is a biotechnology company operating in three product areas: Complex Generics, Biosimilars and Novel Drugs. In Complex Generics product area, the Company develops generic versions of complex drugs that were approved by the United States Food and Drug Administration under New Drug Applications. Enoxaparin Sodium Injection is the Company's first product to receive marketing approval under ANDA. The second complex generic product candidate, M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a complex drug consisting of a synthetic mixture of polypeptide chains. In Biosimilars product area, the Company is seeking to develop biosimilar versions of biologic medicines that were approved by the FDA under Biologics License Applications. Biologics are complex mixtures, and the Company unlocks their structural subtleties using an approach that is similar to the one it uses in the development of complex generics. Novel Drugs program uses the established characterization and process engineering capabilities from complex generics and biosimilars programs with a focus on polysaccharides and therapeutic proteins. Momenta were originally founded to develop novel drugs and it remains the long term goal for the Company. As with the complex generics and biosimilars the Company's platform gives a detailed understanding of the complex structures of novel product candidates, their associated manufacturing processes and controls, and the targeted biologic systems. The Company license or own a patent portfolio of over 95 patent families, each of which includes United States patent applications and/or issued patents as well as foreign counterparts. The Company relies on contract manufacturers since it does not own facilities for manufacturing any products.
» More Articles for MNTA

Headlines

Articles On GuruFocus.com
Very Low P/E Stocks Joel Greenblatt selected Dec 22 2011 
Momenta Pharmaceuticals Inc. (MNTA) SVP, CFO Richard P Shea sells 979 Shares Feb 24 2011 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 45,296 Shares Aug 06 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 7,800 Shares Mar 12 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 32,200 Shares Mar 10 2010 
Momenta Pharmaceuticals Inc. (MNTA) COO Stephen B Brugger sells 1,413 Shares Mar 03 2010 

More From Other Websites
MOMENTA PHARMACEUTICALS INC Financials Mar 07 2015
Teva, Generics File Briefs In Copaxone Patent Re-Appeal Mar 05 2015
Momenta Pharmaceuticals Announces Publication Revealing Development of a Novel Process to Generate... Mar 02 2015
Momenta Pharmaceuticals Announces Publication Revealing Development of a Novel Process to Generate... Mar 02 2015
10-K for Momenta Pharmaceuticals, Inc. Mar 01 2015
MOMENTA PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 27 2015
Momenta Pharmaceuticals to Webcast Presentation at Cowen and Company's 35th Annual Health Care... Feb 26 2015
MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Other Events Feb 23 2015
Copaxone Patent Case Re-Appeal Expedited by Court Feb 21 2015
Copaxone Patent Case Re-Appeal Schedule Proposed by Parties Feb 20 2015
Street Talk: CELG, RH, CTL, RAX & MNTA Feb 18 2015
Momenta (MNTA) Posts Wider-than-Expected Loss in Q4 - Analyst Blog Feb 18 2015
Momenta Pharmaceuticals to Webcast Presentation at Cowen and Company's 35th Annual Health Care... Feb 18 2015
Momenta Pharmaceuticals Inc Earnings Call scheduled for 10:00 am ET today Feb 17 2015
MOMENTA PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement,... Feb 17 2015
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results Feb 17 2015
Momenta reports 4Q loss Feb 17 2015
Momenta reports 4Q loss Feb 17 2015
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results Feb 17 2015
Q4 2014 Momenta Pharmaceuticals Inc Earnings Release - Before Market Open Feb 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK